Primary Record
Oprozomib
- In stock
- 1,667 g
- Purity
- 98.2 %
- CAS
- 935888-69-0
Compound Identifiers & Properties
- CAS
- 935888-69-0
- PubChem CID
- 25067547
- SMILES
- CC1=NC=C(S1)C(=O)N[C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)[C@]3(CO3)C
- Canonical SMILES
- COC[C@H](NC(=O)c1cnc(C)s1)C(=O)N[C@@H](COC)C(=O)N[C@@H](Cc1ccccc1)C(=O)[C@@]1(C)CO1
Names & Synonyms
- Oprozomib
- ONX-0912
- 935888-69-0
- oprozomibum
- Oprozomib (ONX 0912)
- Oprozomib [USAN]
- ONX 0912
- Oprozomib (ONX-0912)
- PR-047
- Oprozomib [USAN:INN]
- Onx0912(oprozomib)
- OPROZOMIB [INN]
- Oprozomib (USAN/INN)
- RefChem:928244
- D0F9BT
- UNII-MZ37792Y8J
- OPROZOMIB [WHO-DD]
- MZ37792Y8J
- C25H32N4O7S
- Oprozomib (ONX-0912)?
- MFCD25976563
- PR 047
- DTXSID201025950
- GTPL8739
- orb1301126
- SCHEMBL1709971
- CHEMBL2103884
- Proteasome Inhibitor ONX 0912
- EX-A332
- ONX0912
- SWZXEVABPLUDIO-WSZYKNRRSA-N
- DTXCID801510202
- GLXC-90132
- AOB87341
- BCP07603
- 2614AH
- BDBM50398607
- NSC766254
- PR-141
- PR-924
- PR-928
- ZINC43202141
- AKOS028109171
- ACN-039825
- CS-2767
- DB11991
- EBC-446057
- FO65113
- NSC-766254
- QC-9273
- NCGC00345799-01
- NCGC00345799-02
- NCGC00345799-04
- AS-17020
- BC600600
- HY-12113
- N-((S)-3-methoxy-1-(((S)-3-methoxy-1-(((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide
- A1934
- NS00072552
- J2.980.600D
- A14181
- D10318
- O-sec-Butyl methyl(1-phenylethyl)carbamothioate
- S-7831
- A857422
- Q27088209
- N-[(2S)-3-methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide
- O-Methyl-N-((2-methylthiazol-5-yl)carbonyl)-L-seryl-O-methyl-N-((1S)-1-benzyl-2-((2R)- 2-methyloxiran-2-yl)-2-oxoethyl)-L-serinamide
- 4-[4-(Dimethylamino)phenoxy]-3-iodo-N,N-dimethylaniline
- Carbamothioic acid, methyl(1-phenylethyl)-, S-propyl ester
- (2S)-3-methoxy-2-[(2S)-3-methoxy-2-[(2-methyl-1,3-thiazol-5-yl)formamido]propanamido]-N-[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]propanamide
- 5-ethyl-2-[4-(5-ethyl-1,3-benzoxazol-2-yl)phenyl]-1,3-benzoxazole
- L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-
- N-((S)-3-methoxy-1-((S)-3-methoxy-1-((S)-1-((R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-ylamino)-1-oxopropan-2-ylamino)-1-oxopropan-2-yl)-2-methylthiazole-5-carboxamide
- ONX 0912; PR 047; ONX-0912; PR-047; ONX0912; PR047
- Proteasome inhibitor (oral, cancer), Proteolix Inc/Onyx Pharmaceuticals Inc
- Proteasome inhibitor program (oral, cancer), Onyx Pharmaceuticals/Ono Pharmaceutical
- (2S)-3-methoxy-2-((2S)-3-methoxy-2-((2-methyl-1,3-thiazol-5-yl)formamido)propanamido)-N-((2S)-1-((2R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)propanamide
- 93589-60-7
- 93589-79-8
- 93590-79-5
- 93590-86-4
- L-Serinamide, O-methyl-N-((2-methyl-5-thiazolyl)carbonyl)-L-seryl-O-methyl-N-((1S)-2- ((2R)-2-methyl-2-oxiranyl)-2-oxo-1-(phenylmethyl)ethyl)-
- L-Serinamide, O-methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-seryl-O-methyl-N-[(1S)-2-[(2R)-2-methyl-2-oxiranyl]-2-oxo-1-(phenylmethyl)ethyl]-
- N-((2S)-3-methoxy-1-(((2S)-3-methoxy-1-(((2S)-1-((2R)-2-methyloxiran-2-yl)-1-oxo-3-phenylpropan-2-yl)amino)-1-oxopropan-2-yl)amino)-1-oxopropan-2-yl)-2-methyl-1,3-thiazole-5-carboxamide
- N-[(1S)-2-[[(1S)-2-[[(1S)-1-benzyl-2-[(2R)-2-methyloxiran-2-yl]-2-oxo-ethyl]amino]-1-(methoxymethyl)-2-oxo-ethyl]amino]-1-(methoxymethyl)-2-oxo-ethyl]-2-methyl-thiazole-5-carboxamide
- O-Methyl-N-((2-methylthiazol-5-yl)carbonyl)-L-seryl-O-methyl-N-((1S)-1-benzyl-2-((2R)-2-methyloxiran-2-yl)-2-oxoethyl)-L-serinamide
- O-Methyl-N-[(2-methyl-5-thiazolyl)carbonyl]-L-Ser-O-methyl-L-Ser-N-[(1S)-2-[(2R)-2-methyloxiranyl]-2-oxo-1-benzylethyl]NH2
- PR-047|||ONX-0912|||N-[(2S)-3-Methoxy-1-[[(2S)-3-methoxy-1-[[(2S)-1-[(2R)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide